Influence of data display formats on physician investigators' decisions to stop clinical trials: Prospective trial with repeated measures

Linda S. Elting, Charles G. Martin, Scott B. Cantor, Edward B. Rubenstein

Research output: Contribution to journalArticlepeer-review

117 Scopus citations

Abstract

Objective. To examine the effect of the method of data display on physician investigators' decisions to stop hypothetical clinical trials for an unplanned statistical analysis. Design. Prospective, mixed model design with variables between subjects and within subjects (repeated measures). Setting. Comprehensive cancer centre. Participants. 34 physicians, stratified by academic rank, who were conducting clinical trials. Interventions. Participants were shown tables, pie charts, bar graphs, and icon displays containing hypothetical data from a clinical trial and were asked to decide whether to continue the trial or stop for an unplanned statistical analysis. Main outcome measure. Percentage of accurate decisions with each type of display. Results. Accuracy of decisions was affected by the type of data display and positive or negative framing of the data. More correct decisions were made with icon displays than with tables, pie charts, and bar graphs (82% v 68%, 56% and 43%, respectively; P = 0.03) and when data were negatively framed rather than positively framed in tables (93% v 47%; P = 0.004). Conclusions. Clinical investigators' decisions can be affected by factors unrelated to the actual data. In the design of clinical trials information systems, careful consideration should be given to the method by which data are framed and displayed in order to reduce the impact of these extraneous factors.

Original languageEnglish (US)
Pages (from-to)1527-1531
Number of pages5
JournalBritish Medical Journal
Volume318
Issue number7197
DOIs
StatePublished - Jun 5 1999

ASJC Scopus subject areas

  • General Medicine

Fingerprint

Dive into the research topics of 'Influence of data display formats on physician investigators' decisions to stop clinical trials: Prospective trial with repeated measures'. Together they form a unique fingerprint.

Cite this